HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal US management

This article was originally published in The Rose Sheet

Executive Summary

Laurent Attal will succeed Jean-Paul Agon as president and CEO of L'Oréal USA, the company announces March 11. Most recently, Attal served as head of the Active Cosmetics Division, which includes the Vichy, La Roche Posay and Inneov brands. He began his career with L'Oréal in 1986, where he managed several business units in France before his appointment to CEO of the Vichy brand in 1994. L'Oréal has been looking for a replacement for Agon since the exec was appointed to succeed Lindsay Owen-Jones as CEO of the company, a role he will fully assume in 2006 (1"The Rose Sheet" Feb. 21, 2005, p. 5)...

You may also be interested in...



L’Oréal Taps Agon To Lead Business; Owen-Jones To Remain Chairman

L'Oréal USA President Jean-Paul Agon will succeed Chairman and CEO Lindsay Owen-Jones at the helm of the French beauty company in 2006 under a new management structure in which Owen-Jones will retain his chairmanship

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel